Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Juli 2026 19:30 ET | Quelle: Custom Market Insights

[Latest] Global Neonatal Infant Care Market Size/Share Worth USD 5.59 Billion by 2035 at a 6.21% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 02, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neonatal Infant Care Market Size, Trends and Insights By Product Type...
29. Juni 2026 10:30 ET | Quelle: Custom Market Insights

[Latest] Global Neonatal Infant Care Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Neonatal Infant Care Market Size, Trends and Insights By Product Type...
24. Juni 2026 09:30 ET | Quelle: Custom Market Insights

[Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

Austin, TX, USA, June 24, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Neonatal Intensive Care Respiratory Devices Market Size, Trends and Insights By...
23. Juni 2026 11:00 ET | Quelle: Lungpacer Medical USA Inc.

Lungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs

Data shows transvenous phrenic nerve stimulation reduces lung collapse and significantly increases availability of lungs that meet transplant criteria
19. Juni 2026 03:30 ET | Quelle: Kither Biotech

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

Kither Biotech announces the successful completion of its Phase 1 clinical study of KIT2014 in healthy participants.
18. Mai 2026 11:30 ET | Quelle: Upstream Bio

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and...
14. Mai 2026 16:30 ET | Quelle: Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
07. April 2026 17:30 ET | Quelle: Custom Market Insights

Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Austin, TX, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Anesthesia and Respiratory Devices Market Size, Trends and Insights By Product...
31. März 2026 16:20 ET | Quelle: Edesa Biotech, Inc.

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
24. Februar 2026 09:15 ET | Quelle: Edesa Biotech, Inc.

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files...

Nächste Seite